

**Original Article****Open Access****Vaginal carriage of *Streptococcus agalactiae* among pregnant women in Ouagadougou, Burkina Faso***¹Ky/Ba, A., ¹Ouattara, A., ²Issa, T., ³Ky, A. Y., ¹Ki, C., ²Sanou, M., and ⁴Sanou, I.¹Bogodogo University Teaching Hospital, Ouagadougou, Burkina Faso²Charles De Gaulle Paediatric University Teaching Hospital, Ouagadougou, Burkina Faso³World Vision International/ Burkina Office, Ouagadougou, Burkina Faso⁴Tingandogo University Teaching Hospital, Ouagadougou, Burkina Faso*Correspondence to: absetou@yahoo.fr; +22670120520**Abstract:**

Background: Group B *Streptococcus* (GBS) is one of the main bacteria responsible of serious neonatal infections. Neonatal transmission is very high at the end of pregnancy between the 34th and 38th week of gestation, and the systematic screening of GBS is strongly recommended in Burkina Faso. The objective of this study was to assess the prevalence of GBS carriage among pregnant women in Ouagadougou, Burkina Faso.

Methodology: This was a cross-sectional study of 300 pregnant women in their third trimester of pregnancy, conducted between July and November 2020. Vaginal sample was collected from each of the pregnant women during prenatal consultations. The samples were cultured on blood agar and the isolated pathogens were identified using the BD Phoenix M50 automated system. Antibiotic sensitivity test was performed on each isolate according to the recommendations of the CA-SFM-EUCAST 2020.

Results: Of the 300 women, 12 samples were positive for GBS, giving a carriage rate of 4.0%. All the GBS isolates were susceptible to ampicillin, cefotaxime, vancomycin and nitrofurantoin. On the other hand, resistance was encountered against penicillin G, erythromycin and trimethoprim-sulfamethoxazole. None of the risk factors assessed was statistically predictive of vaginal carriage of GBS in the pregnant women.

Conclusion: Vaginal carriage of GBS remains relevant. Pending the introduction of an effective vaccine in Burkina Faso, a systematic screening policy for GBS in pregnant women would help reduce perinatal infections from GBS, and the attendant neonatal and infant mortality.

Keywords: *Streptococcus agalactiae*, Group B streptococcus, vaginal carriage, risk factors, pregnancy

Received Feb 6, 2024; Revised Apr 02, 2024; Accepted Apr 03, 2024

Copyright 2024 AJCEM Open Access. This article is licensed and distributed under the terms of the Creative Commons Attribution 4.0 International License <http://creativecommons.org/licenses/by/4.0/>, which permits unrestricted use, distribution and reproduction in any medium, provided credit is given to the original author(s) and the source. Editor-in-Chief: Prof. S. S. Taiwo

Portage vaginal de *Streptococcus agalactiae* chez les femmes enceintes à Ouagadougou, Burkina Faso*¹Ky/Ba, A., ¹Ouattara, A., ²Issa, T., ³Ky, A. Y., ¹Ki, C., ²Sanou, M., et ⁴Sanou, I.¹Hôpital Universitaire de Bogodo, Ouagadougou, Burkina Faso²Hôpital universitaire Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso³Vision Mondiale Internationale/Bureau Burkina, Ouagadougou, Burkina Faso⁴Hôpital Universitaire de Tingandogo, Ouagadougou, Burkina Faso*Correspondance à: absetou@yahoo.fr; +22670120520**Résumé:**

Contexte: Le streptocoque du groupe B (SGB) est l'une des principales bactéries responsables d'infections néonatales graves. La transmission néonatale est très élevée en fin de grossesse entre la 34^{ème} et la 38^{ème} semaine de gestation, et le dépistage systématique du SGB est fortement recommandé au Burkina Faso. L'objectif de cette étude était d'évaluer la prévalence du portage du SGB chez les femmes enceintes à Ouagadougou, au Burkina Faso.

Méthodologie: Il s'agit d'une étude transversale portant sur 300 femmes enceintes dans leur troisième trimestre de grossesse, réalisée entre juillet et novembre 2020. Un échantillon vaginal a été prélevé sur chacune des femmes enceintes lors de consultations prénatales. Les échantillons ont été cultivés sur gélose au sang et les pathogènes isolés ont été identifiés à l'aide du système automatisé BD Phoenix M50. Un test de sensibilité aux antibiotiques a été réalisé sur chaque isolat selon les recommandations du CA-SFM-EUCAST 2020.

Résultats: Sur les 300 femmes, 12 échantillons étaient positifs au SGB, soit un taux de portage de 4,0%. Tous

les isolats de GBS étaient sensibles à l'ampicilline, au céfotaxime, à la vancomycine et à la nitrofurantoïne. En revanche, une résistance a été rencontrée contre la pénicilline G, l'érythromycine et le triméthoprime-sulfaméthoxazole. Aucun des facteurs de risque évalués n'était statistiquement prédictif du portage vaginal du SGB chez les femmes enceintes.

Conclusion: Le portage vaginal du SGB reste d'actualité. En attendant l'introduction d'un vaccin efficace au Burkina Faso, une politique de dépistage systématique du SGB chez les femmes enceintes contribuerait à réduire les infections périnatales dues au SGB et la mortalité néonatale et infantile qui en découle.

Mots-clés: *Streptococcus agalactiae*, streptococcus du groupe B, portage vaginal, facteurs de risque, grossesse

Introduction:

Pregnancy-related illnesses and deaths remain very high. In 2015, it was estimated worldwide that 303,000 women died from pregnancy-related causes; 2.7 million children died during their first 28 days of life and 2.6 million children were stillborn (1,2). Among the causes of maternal and child mortality and morbidity, infections held an important place. Indeed, bacterial, viral or parasitic infections are common during pregnancy (3). *Streptococcus agalactiae* or Lancefield group B streptococcus (GBS), is an encapsulated Gram-positive commensal bacteria of the digestive and vaginal tract found in 20 to 30% of healthy adults (30). Group B streptococcus is considered the main agent involved in maternal-fetal infections, in utero fetal death, septicemia and meningitis in full-term newborns in industrialized countries (1,4,5).

In general, the prevalence of GBS colonization varies between countries and with figures ranging from 1.8% to 81.09% (1,6-7). Carriage rates are 10% in France (8), 26.5% in the United States of America (9), 18.12% in Thailand (10) and 23.7% in Belgium (11). In West Africa, the carriage rate was 12.7% in the city of Abidjan (Ivory Coast) (12), and 18% in Nigeria (13). It is very likely that GBS colonizes virtually all women at some point, intermittently or transiently (1), with carriage increasing with the age of pregnancy (7). Invasive infection occurs after vertical transmission from the rectovaginal sphere of the mother and 1 to 2% of newborns of colonized mothers develop neonatal infections in the first seven days after birth (14,15). In a study in Tunisia, a history of spontaneous miscarriages was associated with carriage of group B streptococcus, with newborns whose mothers who had positive samples having a significantly lower birth weight than those who did not (5).

Prevention of neonatal infection is based on GBS screening in pregnant women and the administration of antibiotics intrapartum (5). Since the Millennium Development Goals (MDGs) for maternal and child health were not achieved in 2015, those for sustainable development (SDGs) were set to, among other things, offer new opportunities for improving maternal and child health by 2030 (16, 17). Given the absence of a real GBS infection prevention in children guidelines in the health

system of Burkina Faso, the present study on the vaginal carriage of GBS in women in the third trimester of pregnancy in the health district of Bogodogo, which objective was to assess the prevalence of GBS carriage among these women in Ouagadougou, with the aim of contributing to the improvement of maternal and child health indicators.

Materials and method:

Study setting:

The study was conducted in the health facilities (Medical Center of Saaba, CSPS of Wemtenga, Dassagho, and sector 30) of the health district of Bogodogo, in the city of Ouagadougou (where vaginal samples were collected) and bacteriological analysis of samples at the biomedical analysis laboratory of the University Teaching Hospital of Bogodogo (CHUB).

Study design period of study:

This was a descriptive cross-sectional study that determined the prevalence of vaginal carriage of group B streptococcus in pregnant women. The study took place from July 2020 to November 2020.

Ethical consideration:

Written authorization from the Regional Director of Health of the Centre Region as well as the agreements of principle from the managers of the health centers were obtained beforehand. In addition, informed consent of the women was a prerequisite for their inclusion in the study. The anonymity of the women and confidentiality were preserved.

Study population and participants:

The study population were pregnant women receiving prenatal consultation in different health facilities in Ouagadougou. The inclusion criteria were pregnant women in the 3rd trimester of pregnancy seen in prenatal consultation and women who voluntarily agreed to participate in the study. Exclusion criteria were women under antibiotic therapy within 72 hours preceding collection, and women with a contraindication to vaginal sampling or who have not given consent to participate in the study.

Study sample size calculation:

The sample size was calculated using the formula; $n = t^2 P(1-P)/e^2$ for *S. agalactiae*

carriage prevalence of 22.0% ($p=0.22$), the highest carriage rate in Africa (18). For a confidence level of 95%, $t=1.96$ and $e=5\%$ precision, giving the calculated minimum sample size of 264, but 300 women were subsequently enrolled into the study.

Data collection:

Data collection from each pregnant women was done using a designed data collection form to obtain information on sociodemographic characteristics, obstetric history, and current pregnancy parameters.

Biological samples collection and laboratory analyses:

Each woman had a vaginal sample taken using a sterile cotton swab from the distal third of the vagina. The swabs were immediately introduced into tubes containing Todd-Hewitt with Colistin and Nalidixic Acid (CNA) broth, and transported to the laboratory for incubation at 37°C for 18-24 hours.

Subculture of the incubated broth was done on agar supplemented with 5% defibrinated sheep blood containing CNA, and incubated at 37°C for 24 hours in the presence of 10% CO₂. GBS colonies on fresh sheep blood agar appeared as small (1 to 2 mm in diameter), rounded, and present a zone of β haemolysis resulting in a perfectly transparent clear halo around the colony which corresponds to total lysis of red blood cells. Preliminary identification of GBS was by Gram stain microscopy of the colonies which showed Gram-positive cocci in chains of varying length and negative catalase test. Confirmatory phenotypic identification of GBS species was carried out using the automated BD Phoenix M50 instrument.

Antibiotic susceptibility of the GBS isolates was done by the disc diffusion technique on Muller-Hinton agar medium supplemented with 5% fresh defibrinated sheep blood, and results interpreted according to the recommendations of the 2020 Antibiogram Committee of the French Society of Microbiology - European Committee on Antimicrobial Susceptibility Testing (CA-SFM-EUCAST 2020) (18).

Data analysis:

Data were entered into Excel and Microsoft Word, and statistical analysis was done using EPI-INFO software version 7.2.3.1. Pearson's Chi-square test was used to compare data with $p<0.05$ considered as statistical significance.

Results:

A total of 300 pregnant women were enrolled into the study. The mean age of the women was 25.2±5.5 years with range of 15-42 years. A total of 36 (12.0%) cultures were positive for microbial pathogens but 12 were positive for GBS isolates, giving vaginal carriage rate in the study to be 4.0%. The mean age of women with vaginal GBS is 25.1±5.5 years with range of 19-38 years (Table 1).

The antibiotic susceptibility of the GBS isolates showed 100% sensitivity to ampicillin, cefotaxime, amoxicillin-clavulanic acid, vancomycin and nitrofurantoin but 23.0% of the isolates were resistant to penicillin G. Resistance rate to macrolides was 23.0% to erythromycin and 25.0% to lincomycin), 75.0% to quinolone (ciprofloxacin), 92.0% to tetracycline and 100.0% to trimethoprim-sulfamethoxazole (Fig 1).




Fig 1: Susceptibility of Group B streptococcus (GBS) isolates to selected antibiotics

Table 1: Prevalence of GBS with respect to sociodemographic and obstetric characteristics of the women

Variables	Number of women (n=300)	Number of GBS isolated	Percentage (%)	p value
Age group (years)				
15-19	48	1	2.1	0.054
20-34	238	8	3.4	
≥ 35	14	3	21.4	
Educational level				
Not educated	156	05	3.2	0.77
Primary	85	05	5.9	
Secondary	44	01	2.3	
Tertiary	15	01	6.7	
Marital status				
Married	279	11	3.9	0.77
Single	21	1	4.8	
Occupation				
Housewife	232	8	3.4	0.454
Employed (informal sector)	68	4	5.9	
Number of gestation				
1-2	195	6	3.1	0.09
3-4	81	3	3.7	
≥ 5	24	3	12.5	
Parity				
<4	284	2	0.7	0.16
≥ 4	16	10	62.5	

Discussion:

In the present study, 300 pregnant women were enrolled, the minimum age was 15 years with an average of 25.19 years. The age group of 20 to 34 was the most represented, with 238 women or 79.33%. Among these enrolled women, 279 (93%) lived as a couple. These findings are observed in other studies in Africa, notably that carried out in Ethiopia in 2016 by Mengist et al., who found an average age of 26 years (19), as well as that carried out by Salou et al., (20) in Togo. In the African context, the early age of marriage of the girl could explain this significant frequency of young people and young adults among the participants in the present study. It appears from this study that most of these parturient women (77.33%) had no income and more than 94% of them were out of school or limited to a primary or secondary level.

Group B streptococcus was isolated from vaginal samples of the 300 participants, representing a vaginal colonization rate of 4.0%. These results are close (4.7%) to those of Nyampa, (21) in 2018 who also conducted his study on pregnant women in the city of Ouagadougou. It is the same as that led by Zaïdi, in Fez (Morocco), who also found in 2018 a GBS carriage rate (4.69%) comparable to ours (22). The Ouédraogo team, in their work in 2017 on pregnant women at all ages of pregnancy in Bobo Dioulasso, reported 6.05% (23). In addition, Mounerou et al., reported vaginal carriage rate that is a little lower than ours (2.5%) in 2015 in Togo (20).

Generally speaking, the vaginal carri-

age rate of GBS has been reported to vary from continent to continent, country to country, and sometimes within the same country. Thus, on the African continent, several recent studies conducted by different authors have given percentages higher than ours; Gbonon et al. reported carriage rate of 12.7% in the city of Abidjan (Ivory Coast) (12). In 2016, Bassir et al., (24) in Marrakech Morocco, reported a rate of 20.5%, Mahmoud (25) in Fez, Morocco in 2010 reported a rate of 23.0%, Mengist et al., (19) in Ethiopia reported a rate of 19% and Ezeonu in 2014 in Nigeria reported a rate of 18.0% (13). Carriage frequencies range from 10.0% in France (8), 18.12% in Thailand (10), 23.7% in Belgium (11) to 26.5% in the United States of America (9).

The variation in rates could be attributed to a number of factors including maternal hygiene and the choice of sampling site. Some researchers collected anal and/or rectal samples with vaginal samples such as in the studies carried out in Morocco and Cameroon (25,26) where high rates of GBS carriage of 23.3% and 14.0% respectively were reported. The laboratory techniques used to detect the pathogens are also factors in the variability of results between studies. Thus, researchers who used PCR reported very high prevalence of 43.8% (27).

Regarding the parameters studied in the present study which included age, level of education, marital status, profession, weight, number of gestures, parity, gestational age, high blood pressure, diabetes and anaemia, none was significantly associated with maternal carriage of GBS. Gbonon et al., (12) in Abi-

djan in 2006 and other researchers (28,29) likewise did not find statistically significant association between socio-demographic and obstetric factors, and the carriage of GBS by pregnant women. On the other hand, Joachim et al., (30) in Tanzania reported an increase in carriage when the age of pregnancy was advanced, finding 46.7% in women with gestational age of 41 to 42 weeks.

Concerning the sensitivity profile to antibiotics such as ampicillin, cefotaxime, amoxicillin-clavulanic acid, vancomycin and nitrofurantoin had very good activity on the GBS strains isolated in this study. Similar results were reported by Ferjani et al., (7). Numerous studies have reported a lack of resistance of GBS to penicillin G (7,31,20,32,33). In our series, 23.0% of the isolated strains were resistant to penicillin G. The research teams of Agricola (30) and those of Ouedraogo (23) also reported resistance of GBS to penicillin G of 9.4% and 10.8% respectively. High rates of GBS resistance were observed against macrolides (erythromycin 23%, lincomycin 25%) as well as quinolones (ciprofloxacin 75%), cyclins (92.0%), and trimethoprim-sulfamethoxazole (100.0%). This high level of GBS resistance could be a consequence of the inappropriate use of these antibiotics which are relatively easy to access for the population in Burkina Faso. Added to this is an inadequacy of regulations regarding the prescription, distribution and consumption of antibiotics in the context of Burkina Faso.

Conclusion:

Group B streptococcus can be transmitted from mother to child during or before delivery and is responsible for fetal or neonatal infection. Vaginal GBS carriage was high among women in the 3rd trimester of pregnancy in the Bogodogo health district, with no predictive factors. The most commonly used antibiotics are increasingly ineffective against these bacteria. Given the non-negligible prevalence of maternal GBS carriage in our conditions and the absence of real predictive factors for vaginal carriage, it seems desirable in the context of the prevention of maternal-fetal GBS infections to establish a policy of systematic screening near the end of pregnancy for all pregnant women in order to reduce neonatal mortality.

Acknowledgements:

The authors acknowledge the Bogodogo University Hospital for authorizing the analyzes within the laboratory, and the Central Regional Health Directorate for authorizing the enrollment of pregnant women.

Contributions of authors:

KBA, OA conceived the study idea, led the conduct of the study and editing of the manuscript. KBA, TI and KC were responsible for carrying out the bacteriological diagnostic activities. KAB and KAY were responsible for English translation activities. KAB, OA, TI, KC, KAY, SM, and SI were responsible for the final editing of the manuscript. All authors approved the final manuscript submitted.

Source of funding:

Authors receive no external funding

Conflict of interest:

No conflict of interest is declared.

References:

- Gibbs, R. S., Schrag, S., and Schuchat, A. Perinatal Infections Due to Group B Streptococci: Obstet Gynecol. 2004; 104 (5, Part 1): 1062-1076.
[doi:10.1097/01.AOG.0000144128.03913.c2](https://doi.org/10.1097/01.AOG.0000144128.03913.c2)
- World Health Organization. Quality, equity, dignity: the network to improve quality of care for maternal, newborn and child health – strategic objectives, 2018
- Judlin, P., and Thiébauges, O. La surveillance microbiologique de la femme enceinte: quels examens réaliser durant la grossesse? Gynécologie Obstétrique Fertilité. 2005; 33 (11): 907-913.
<https://doi.org/10.1016/j.gyobfe.2005.08.019>
- Six, A., Joubrel, C., Tazi, A., and Poyart, C. Infections materno-fœtales à *Streptococcus agalactiae*. La Presse Médicale, 2014; 43 (6, Part 1): 706-714.
<https://doi.org/10.1016/j.lpm.2014.04.008>
- Jerbi, M., Hidar, S., Hannachi, N., et al. Facteurs de risque du portage du streptocoque du groupe B chez la femme enceinte à terme: étude prospective à propos de 294 cas, Gynécologie Obstétrique Fertilité. 2007; 35 (4): 312-316.
<https://doi.org/10.1016/j.gyobfe.2007.01.027>
- Tarana, M. N., and Shamsuzzaman, S. M. Detection of Group B Streptococcus in vaginal swab of pregnant women by culture and PCR and their Antibiotic susceptibility pattern in a Tertiary care hospital of Bangladesh. Mymensingh Med J. 2018; 27(3): 567-572.
- Ferjani, A., Abdallah, H. B., Saida, N. B., Gozzi, C., and Boukadida, J. Portage vaginal de *Streptococcus agalactiae* chez la femme enceinte en Tunisie : facteurs de risque et sensibilité aux antibiotiques des isolats. Bull Soc Pathol Exot. 2006; 99 (2): 99-102.
- Agence nationale d'accréditation et d'évaluation en santé. Prévention anténatale du risque infectieux bactérien néonatal précoce. J Gynecol Obstet Biol Reprod (Paris). 2003; 32: 68-74
- Yancey, M. K., Schuchat, A., Brown, L. K., Ventura, V. L., and Markenson, G. R. The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol. 1996; 88 (5): 811-815
[doi: 10.1016/0029-7844\(96\)00320-1](https://doi.org/10.1016/0029-7844(96)00320-1)
- Kovavisarach, E., Ying, W. S., and Kanjanahareutai, S. Risk factors related to group B streptococcal colonization in pregnant women in labor. J Med Assoc Thai. 2007; 90 (7): 1287-1292.

11. Lorquet, S., Melin, P., Minon, J-M., et al. Le streptocoque du groupe B en clinique anténatale et en salle de travail : un problème d'attitude systématique. *J Gynécologie Obstétrique Biol Reprod.* 2005 ; 34 (2) : 115-127. [doi:10.1016/S1637-4088\(05\)86229-7](https://doi.org/10.1016/S1637-4088(05)86229-7)
12. Gbonon, V., Ouattara, N., Guessennd, N., Faye-Ketté, H., and Dosso, M. Facteurs de risque de portage du Streptocoque du groupe B chez la parturiente à terme : Enquête réalisée en 2006 dans les maternités d'Abidjan. *Rev Bio Afr N.* 2012; 40-46.
13. Ezeonu, I. M., and Agbo, M. C. Incidence and anti-microbial resistance profile of Group B Streptococcus (GBS) infection in pregnant women in Nsukka, Enugu State, Nigeria. *Afr J Microbiol Res.* 2014; 8 (1): 91-95. <https://doi.org/10.5897/AJMR12.2307>
14. De Steenwinkel, F. D. O., Tak, H. V., Muller, A. E., Nouwen, J. L., Oostvogel, P. M., and Mocumbi, S. M. Low carriage rate of group B streptococcus in pregnant women in Maputo, Mozambique, *Trop Med Int Health.* 2008; 13 (3): 427-429. [doi:10.1111/j.1365-3156.2008.02018.x](https://doi.org/10.1111/j.1365-3156.2008.02018.x).
15. Musleh, J., and Al Qahtani, N. Group B Streptococcus colonization among Saudi women during labor. *Saudi J Med Sci.* 2018; 6 (1): 18-22. [doi:10.4103/sjmms.sjmms_175_16](https://doi.org/10.4103/sjmms.sjmms_175_16).
16. Kuruville, S., Bustreo, F., Kuo, T., et al. The global strategy for women's, children's and adolescents' health (2016–2030): a roadmap based on evidence and country experience. *Bull World Health Organ.* 2016; 94(5): 398-400. [doi: 10.2471/BLT.16.170431](https://doi.org/10.2471/BLT.16.170431)
17. United Nations, General Assembly: Transforming our world: The 2030 agenda for sustainable development, 2015
18. Gizachew M., Tiruneh, M., Moges, F., and Tessema, B. *Streptococcus agalactiae* maternal colonization, antibiotic resistance and serotype profiles in Africa: a meta-analysis. *Ann Clin Microbiol Antimicrob.* 2019; 18 (1): 14 [doi:10.1186/s12941-019-0313-1](https://doi.org/10.1186/s12941-019-0313-1)
18. CA-SFM. Comité de l'Antibiogramme de la société Française de Microbiologie. Recommandations CA-SFM-EUCAST 2020, Version avril 2020 V.1.1.
19. Mengist, A., Kannan, H., and Abdissa, A. Prevalence and antimicrobial susceptibility pattern of anorectal and vaginal group B Streptococci isolates among pregnant women in Jimma, Ethiopia. *BMC Res Notes.* 2016; 9 (1): 351. [doi:10.1186/s13104-016-2158-4](https://doi.org/10.1186/s13104-016-2158-4)
20. Salou, M., Dagnra, A. Y., Hondégla, A., et al. Group B Streptococcal Carriage Rate in Vaginal of Pregnant Women in Third Trimester in Lomé, Togo. *World J Prev Med.* 2015; 3 (1): 7-10. [doi:10.12691/jpm-3-1-2](https://doi.org/10.12691/jpm-3-1-2)
21. Nyampa, H. portage de *Streptococcus agalactiae* (groupe B) chez les femmes enceintes à Ouagadougou, Burkina Faso. [Mémoire : Master II bactériologie-virologie]. Bobo Dioulasso: Université catholique de l'Afrique de l'ouest (UCAO/UUB). 2019: 77
22. Zaidi, I, Prévalence des Streptocoques B bêta hémolytiques chez les femmes enceintes, Mémoire, Licence Science & Techniques Sciences Biologiques Appliquées et Santé. Université Sidi Mohamed Ben Abdellah, 2018
23. Ouédraogo, A. S., Sawadogo, Y., Somé, D. A., et al. Prevalence of Group B Streptococcus among Pregnant Women in Bobo-Dioulasso (Burkina Faso). *Open J Med Microbiol.* 2019; 9 (3): 63-76. [doi:4236/ojmm.2019.93008](https://doi.org/10.4236/ojmm.2019.93008)
24. Bassir, A., Dhibou, H., Farah, M., et al. Portage vaginal du streptocoque du groupe B chez la femme enceinte au niveau de la région de Marrakech. *Pan Afr Med J.* 2016; 23: 107. [doi:10.11604/pamj.2016.23.107.9047](https://doi.org/10.11604/pamj.2016.23.107.9047).
25. Mahmoud, M., Yahyaoui, G., Benseddik, N., Saadi, M., Chaara, H., and Melhouf, M. A. Group B *Streptococcus* screening during the third quarter of pregnancy in the CHU Hassan II of fez. *Revue Tunisienne d'Infectiologie.* 2011; 5 (1): 12-15. <https://doi.org/10.80481/revuetest30246>
26. Nkembe, N. M., Kamga, H. G., Baiye, W. A., Chafa, A. B., and Njotang, P. N. *Streptococcus agalactiae* prevalence and antimicrobial susceptibility pattern in vaginal and anorectal swabs of pregnant women at a tertiary hospital in Cameroon. *BMC Res Notes,* 2018; 11: 480. <https://doi.org/10.1186/s13104-018-3589-x>
27. Bidgani, S., Navidifar, T., Najafian, M., and Amin, M. Comparison of group B streptococci colonization in vaginal and rectal specimens by culture method and polymerase chain reaction technique. *J Chin Med Assoc.* 2016; 79 (3): 141-145. [doi:10.1016/j.jcma.2015.06.021](https://doi.org/10.1016/j.jcma.2015.06.021)
28. Jisuvei, S. C., Osoti, A., and Njeri, M. A. Prevalence, antimicrobial susceptibility patterns, serotypes and risk factors for group B streptococcus rectovaginal isolates among pregnant women at Kenyatta National Hospital, Kenya; a cross-sectional study. *BMC Infect Dis.* 2020; 20 (1): 302. [doi:10.1186/s12879-020-05035-1](https://doi.org/10.1186/s12879-020-05035-1).
29. Dashtizade, M., Zolfaghari, M. R., Yousefi, M., and Nazari-Alam, A. Antibiotic susceptibility patterns and prevalence of *Streptococcus agalactiae* rectovaginal colonization among pregnant women in Iran. *Rev Bras Ginecol Obstetrícia.* 2020; 42 (8): 454-459. [doi: 10.1055/s-0040-1710299](https://doi.org/10.1055/s-0040-1710299).
30. Agrícola, J., Matee, M. I., Massawe, F. A., and Lyamuya, E. F. Maternal and neonatal colonisation of group B Streptococcus at Muhimbili National Hospital in Dar es Salaam, Tanzania: Prevalence, risk factors and antimicrobial resistance. *BMC Publ Health.* 2009; 9: 437. [doi:10.1186/1471-2458-9-437](https://doi.org/10.1186/1471-2458-9-437)
31. Onipede, A., Adefusi, O., Adeyemi, A., Adejuyigbe, E., Oyelese, A., and Ogunniyi, T. Group B Streptococcus carriage during late pregnancy in Ile-Ife, Nigeria. *Afr J Clin Exper Microbiol.* 2012; 13 (3): 135-143. [doi:10.4314/ajcem.v13i3.2](https://doi.org/10.4314/ajcem.v13i3.2)
32. Loulergue, J., Couhé, C., Grasmick, C., Laudat, P., and Quentin, R. Sensibilité aux antibiotiques des souches de streptocoque du groupe B de portage vaginal isolées en France, 2003. *BEH.* 2004; 18: 69-70.
33. Quentin, R., Loulergue, J., Mala, L., et al. Streptocoque du groupe B en pathologie humaine: origine des isolats et sensibilité aux antibiotiques. *BEH.* 2006; 45:2005-2007.